Grow Biotech, IPS Specials join forces to offer medicinal cannabis
Category: #health  By Mateen Dalal  Date: 2019-04-02
  • share
  • Twitter
  • Facebook
  • LinkedIn

Grow Biotech, IPS Specials join forces to offer medicinal cannabis

A joint venture will combine IPS Specials’ abilities as a licensed pharma importer with medical cannabis expertise of Grow Biotech

Reports confirm that IPS Specials and Grow Biotech will ink a joint venture agreement for creating a new firm that will provide the only full licensed market access proposition of medicinal cannabis in the U.K. and transform the access to medical cannabis in U.K. and Europe.

Seemingly, the joint venture would combine market capabilities of IPS Specials as a licensed importer of pharmaceuticals with unparalleled medical cannabis expertise of Grow Biotech.

Sources familiar with the matter informed that the new company will directly benefit from IPS’ infrastructure, profound knowledge and full set of licenses. These include Home Office Controlled Drugs Schedule 2, MHRA Specials Manufacturing, and GPhC Registered Pharmacy, besides the unique offerings of Grow Biotech such as cannabis technologists, expert scientists, business developers and ABPI regulated pharmaceutical reps.

The new company will focus on maximizing and supporting patient access. The directors are already involved in advanced discussions with a huge number of leading Licensed Producers (LP), ensuring health care professionals as well as patients have access to a wide selection of the prime cannabis based medicinal products.

New company’s formation is anticipated to be completed and named by the end of this month and in the coming weeks, the very first LP partnerships will also be announced. For UK patients it will become a major part of the solution, especially those who are well treated by cannabis-based medicines.

According to the CEO of Grow Biotech, Ben Langley, through this joint venture, the new company formed with IPS Specials would be focused on positive patient outcomes. With Grow’s deep cannabis knowledge and the track record of deploying and raising capital the company is well placed to facilitate the growth in the UK.

For those uninitiated, on 15 Feb 2019, Grow Biotech and IPS Specials worked jointly to successfully implement the first bulk import of medicinal cannabis from Europe to the UK, with three patients getting their cannabis medicines within 24 hours of the cannabis arriving in the UK.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Deciphera to present data from DCC-3014 trial at CTOS annual meet
Deciphera to present data from DCC-3014 trial at CTOS annual meet
By Mateen Dalal

The ongoing clinical trial of DCC-3014 have shown preliminary anti-tumor activity.    DCC-3014 validates emerging tolerability profile with no Grade 3 or Higher TEAEs.   Encore presentation of data from the INVICTUS Pivotal Phase...

Roches risdiplam meets primary endpoint results in phase 3 trial
Roches risdiplam meets primary endpoint results in phase 3 trial
By Mateen Dalal

Spinal muscular atrophy (SMA) is a genetic neuromuscular condition, affecting approx. 1 in 6,000 babies born globally each year. Numerous healthcare companies throughout the world are putting their best foot forward to develop an effective ...

Disney+ all set for a March 2020 launch in the United Kingdom
Disney+ all set for a March 2020 launch in the United Kingdom
By Mateen Dalal

The entertainment behemoth is launching its much-awaited streaming platform.   Release of more than 300 movies is on the cards. Disney has finally asserted that new streaming service Disney+ will be rolled out soon in the U.K. Disney+ goes...